Cell Therapy Development Platforms
Over the past two decades, significant progress has been made in cell therapy development, paving the way for novel therapies and potential cures for previously intractable diseases. Our company is at the forefront of cell therapy development, dedicated to advancing the understanding and application of this transformative technology. Through rigorous research and innovative approaches, we provide comprehensive cell therapy development services to accelerate research into rare disease therapies.
Overview of Cell Therapies
Cell therapy has emerged as a revolutionary approach in medical science, offering new avenues for treating a wide range of diseases and conditions. By utilizing the therapeutic potential of living cells, cell therapy aims to restore, repair, or replace damaged or dysfunctional cells within the body. This innovative field has gained significant attention in recent years, as it holds immense promise in addressing unmet medical needs and transforming the landscape of healthcare.
Fig.1 Fitting the engineered T cell therapy development process into the conventional drug discovery and development paradigm. (Chen, F., et al., 2019)Cell therapy can be divided into stem cell therapy and immune cell therapy according to cell type. Stem cell therapy uses the differentiation and repair principles of human stem cells to transplant healthy stem cells into the body to repair diseased cells or rebuild normal functioning cells and tissues. Immune cell therapy collects the body's immune cells, cultures them in vitro, and then infuses them back into the body to kill pathogens, cancer cells, and mutated cells in the blood and tissues, break immune tolerance, and activate and enhance the body's immune capabilities.
Cell Therapies for Rare Diseases
Cell therapies offer a promising avenue to address the unique challenges posed by rare diseases. Rare diseases are often caused by genetic mutations. For example, gene editing technology is used to introduce normal genes into the body's stem cells and transplant these stem cells back into the body to restore normal protein production in the body. Cell therapies have made significant progress in the development of several rare diseases.
Table 1 Selected cell-based products for rare diseases. (Bashor, C. J., et al., 2022)
| Cell type | Product name (company or institution) | Indication | Source | Delivery | Phase | Trial ID |
|---|---|---|---|---|---|---|
| T cell | TR004 (Kings' College London) | Crohn's disease | Autologous | i.v. | II | NCT03185000 |
| MSC | NurOwn (Brainstorm Cell Therapeutics) | Multiple sclerosis | Autologous | i.v. | II | NCT03799718 |
| HSC | NA (Bluebird Bio) | Sickle cell disease | Autologous | i.v. | II | NCT03745287 |
| MSC | Prochymal (Osiris) | Graft versus host disease | Allogeneic | i.v. | III | NCT00284986 |
| T cell | Descartes-08 (Cartesian Therapeutics) | Myasthenia gravis | Autologous | i.v. | II | NCT04146051 |
Our Services
Through careful cell selection, understanding of mechanisms of action, robust manufacturing processes, and strict safety considerations, our company provides one-stop cell therapy development services. Our cell therapy development platform provides different cell therapy solutions for different diseases and customer needs and provides efficient methods to accelerate your development of rare disease therapy.
Cell Therapy Development Workflow
Why Choose Us?
Our company offers comprehensive services and technical support for every stage of rare disease research. Our extensive experience in cell therapy development allows us to provide you with customized services as well as comprehensive assistance that can help you move from rare disease therapy development to therapy commercialization. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Chen, F., et al. "Engineered T cell therapies from a drug development viewpoint." Engineering 5.1 (2019): 140-149.
- Bashor, C. J., et al. "Engineering the next generation of cell-based therapeutics." Nature Reviews Drug Discovery 21.9 (2022): 655-675.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
